Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy
Condition(s):HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract CancerLast Updated:October 11, 2023Completed
Hide Studies Not Open or Pending
Condition(s):HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract CancerLast Updated:October 11, 2023Completed
Condition(s):Biliary Tract CancerLast Updated:November 17, 2017Completed
Condition(s):Biliary Tract Cancer; Neoadjuvant, Adjuvant and 1st LineLast Updated:September 29, 2023Recruiting
Condition(s):Biliary Tract CancerLast Updated:January 29, 2021Enrolling by invitation
Condition(s):Advanced or Metastatic Biliary Tract CancerLast Updated:December 10, 2021Unknown status
Condition(s):Advanced or Metastatic Biliary Tract CancerLast Updated:December 29, 2021Recruiting
Condition(s):Biliary Tract CancerLast Updated:February 9, 2024Active, not recruiting
Condition(s):Biliary Tract CancerLast Updated:January 25, 2018Withdrawn
Condition(s):Pancreatic Cancer; Biliary CancerLast Updated:April 4, 2012Completed
Condition(s):Metastatic Biliary Tract CancerLast Updated:February 28, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.